|View printer-friendly version|
|Medtronic Announces CE Mark and European Launch of the Euphora(TM) Semicompliant Coronary Balloon Catheter|
Semicompliant Balloon Brings Greater Deliverability to Combat Challenging Coronary Lesions
DUBLIN - February 16, 2015 - Medtronic plc (NYSE: MDT) today announced the launch of the Euphora(TM) Semicompliant Balloon Dilatation Catheter in countries that recognize the CE (Conformité Européene) mark. The first patient case with the Euphora Semicompliant Balloon Catheter was recently performed by Richard Edwards, M.D., consultant cardiologist at the Freeman Hospital in Newcastle, United Kingdom. It is not available in the United States.
"After performing the first patient case with Euphora, it is the most deliverable balloon catheter I have used," said Dr. Edwards. "The exceptionally low crossing profile and pushability make it ideal for complex situations and workhorse lesions alike."
Pre-dilatation with a semicompliant balloon helps physicians determine lesion characteristics, stent selection and facilitates stent access to the lesions - a crucial step for patients with complex lesions.
The Euphora Semicompliant Balloon Catheter features several design advancements including:
"The Euphora family of balloons is a giant leap forward in balloon technology and builds upon our successful multi-brand strategy, which includes offering premium products at premium prices to help meet different customer needs," said Jason Weidman, vice president and general manager of the Medtronic coronary business. "Along with the previously launched noncompliant version of Euphora, these products exemplify our continued commitment to expand our interventional portfolio with innovative and differentiated technologies that address the needs of cath lab professionals around the world."
The Euphora semicompliant balloon expands Medtronic's interventional portfolio of medical devices across Coronary, Renal Denervation and TAVR, and is the latest in a series of 12 new product introductions planned over the next 2 years.
In collaboration with leading clinicians, researchers and scientists, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers worldwide.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
- end -
i Competitive Bench testing vs. Trek, Emerge(TM), Sprinter(TM) Legend(TM) and Ryujin(TM) Plus balloons. 2.50-mm x 15-mm balloons tested. Bench test data may not be indicative of clinical performance. .
ii Competitive Bench testing vs. Sprinter(TM) Legend(TM) and Emerge. Plus 2.50-mm x 15-mm balloons tested. Bench test data may not be indicative of clinical performance.